Prostate Cancer:

Sirexatamab (DKN-01) in prostate cancer

Posters for the prostate cancer indication

• A Phase 1/2 Multicenter Investigator-Initiated Trial of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) – (Poster)
• A Phase 1/2 Multicenter Investigator-Initiated Trial of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) – (Slides)
• DKK1 defines a non-neuroendocrine subtype of mCRPC with low AR and low PSA expression